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ChallengeV) regularly accounts for severe and often lethal outbreaks among livestock and
humans in Africa. Safe and effective veterinarian and human vaccines are highly needed. We present
evidence that administration of RVF virus-like particles (VLPs) induces protective immunity in mice. In an
accompanying paper, (Habjan, M., Penski, N., Wagner, V., Spiegel, M., Överby, A.K., Kochs, G., Huiskonen, J.,
Weber, F., 2009. Efﬁcient production of Rift Valley fever virus-like particles: the antiviral protein MxA can
inhibit primary transcription of Bunyaviruses. Virology 385, 400–408) we report the production of these VLPs
in mammalian cells. After three subsequent immunizations with 1×106 VLPs/dose, high titers of virus-
neutralizing antibodies were detected; 11 out of 12 mice were protected from challenge and only 1 out of 12
mice survived infection in the control groups. VLP vaccination efﬁciently suppressed replication of the
challenge virus, whereas in the control animals high RNA levels and increasing antibody titers against the
nucleocapsid protein indicated extensive viral replication. Our study demonstrates that the RVF VLPs are
highly immunogenic and confer protection against RVFV infection in mice. In the test groups, the vaccinated
mice did not exhibit any side effects, and the lack of anti-nucleocapsid protein antibodies serologically
distinguished vaccinated animals from experimentally infected animals.
© 2008 Elsevier Inc. All rights reserved.IntroductionRift Valley Fever (RVF) is an emerging infectious disease and
considered as one of the most important viral zoonoses in Africa. The
disease was restricted to the sub-Saharan region of Africa until the
middle of the 1970s. Since then, RVF has become endemic throughout
Africa and more recently RVF has been found also on Arabian
Peninsula (Balkhy and Memish, 2003; Gerdes, 2004).
Epizootics of RVF are characterized by increasing numbers of
abortions and high neonatal mortality. Among adult animals, the
clinical manifestations range from asymptomatic to more severe
conditions like hepatitis and death, although the progression andd at Fax: +49 761 203 6634.
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species (Elliott, 1996). In humans, RVF is considered as a temporarily
incapacitating illness with fever, myalgia, and headache. However,
more severe clinical symptoms—such as encephalitis, ocular disease,
hepatitis, and hemorrhagic fever—have been observed (Al-Hazmi
et al., 2003; Siam et al., 1980). Presently, treatments are symptomatic
combined with an occasional need of intensive care.
The RVF virus (RVFV), a member of the Phlebovirus genera in the
Bunyaviridae family, is transmitted by several different mosquito
species and has an unusual broad range of susceptible animal hosts
(Flick and Bouloy, 2005). As for other members of this family of
viruses, the genetic information is divided into three negative
stranded RNA segments: (S)mall, (M)edium and (L)arge. The L-seg-
ment encodes for the RNA polymerase, and the M- and S-segments
encode for two glycoproteins (GN/GC), the 78 kDa protein and the
nucleocapsid (N) protein, respectively. Furthermore, the RVFV genome
encodes for two non-structural proteins: NSs and NSm of the S and M
segment, correspondingly (Elliott, 1996). The NSs protein is involved
in disruption of the host antiviral response (Billecocq et al., 2004; Le
May et al., 2004) and the NSm protein is reported to suppress
apoptotic pathways in host cells after infection (Won et al., 2007).
Fig. 1. Sero-conversion in mice after VLP vaccination determined by immuno-
ﬂuorescence assay and plaque reduction neutralization tests. Mice sera were collected
after three subsequent VLP immunizations and analyzed for panel A antibody reactivity
towards RVFV-infected mammalian cells and panel B titer of virus neutralizing
antibodies. Two dose groups are represented: mice vaccinated with 1×105 or 1×106
VLPs/dose. No sero-conversion was observed among the control mice and are therefore
excluded from these graphs. The antibody titer was determined as the reciprocal of the
highest positive serum dilution of (panel A) three-fold and (panel B) ﬁve-fold serially
diluted sera, respectively.
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ability of the virus to maintain in newly conquered areas due to the
wide range of mosquito vectors and susceptible hosts, imply that
novel therapeutics and vaccines are necessary. Currently, there are no
registered vaccines for human use. However, a formalin inactivated
virus vaccine for humans has been developed (Kark et al., 1982;
Pittman et al., 1999), although the distribution has been limited to
workers at high-risk occupations. The live attenuated Smithburn
neurotropic strain (Smithburn, 1949) and formalin inactivated virus
vaccines produced in South Africa and Egypt (Metwally, 2008) are
approved for veterinarian use. The Smithburn vaccine is highly
immunogenic, but is teratogenic in pregnant cattle and sheep (Botros
et al., 2006; Coetzer and Barnard, 1977). The formalin inactivated
vaccines are safe, but less immunogenic (Lubroth et al., 2007). Other
vaccine candidates under evaluation are Clone 13 and MP12. Both
have shown promising results in animal trials. Clone 13 is a natural
attenuated isolate from a benign human case in the Central African
Republic (Muller et al., 1995), and MP12 is a chemically attenuated
virus derived from the Egyptianwild-type isolate ZH548 (Caplen et al.,
1985; Vialat et al., 1997). The immunogenicity and pathogenicity of
these candidates have been evaluated in various animal species
(Muller et al., 1995; Morrill et al., 1997). The most extensively tested,
MP12, induced foetal malformations during the ﬁrst trimester (Hunter
et al., 2002). More recently, reverse genetic systems have been
established for RVFV that allow genetic engineering of the virus
genomes and production of recombinant virus particles (Billecocq et
al., 2008; Gerrard et al., 2007; Habjan et al., 2008; Ikegami et al.,
2006). Such techniques have been used to produce attenuated RVFV
particles which have displayed promising results as a vaccine in a
rodent model (Bird et al., 2008). However, inherent problems of live
vaccines are the expensive production due to high biosafety precau-
tions and the risk of side effects such as teratogenicity and infections
in immuno-suppressed individuals. Moreover, replicating RVFV
vaccines could theoretically be spread by mosquitoes.
Another approach for vaccine development is to use virus-like
particles (VLPs) that are formed when the structural (envelope and/or
nucleocapsid) proteins self-assemble to replication-deﬁcient particles.
In comparison to component vaccines based on recombinant or
subunit proteins, VLPs are in general more immunogenic and more
natural in presenting conformational epitopes, and hence, more likely
to induce neutralizing antibodies (Grgacic and Anderson, 2006).
In an accompanying paper, we describe the production of RVF VLPs
inmammalian cells by expressing the viral structural genes alongwith
a Renilla luciferase reporter minigenome (Habjan et al., 2009). These
VLPs have the size, morphology, and protein composition resembling
authentic RVFV particles. They contain nucleocapsids consisting of N
and the reporter RNA minigenome and display the envelope (GN and
GC) proteins at their surface. Moreover, the VLPs can enter target cells
and carry out transcription of the reporter gene, but they cannot
replicate or produce progeny. They can be neutralized by RVFV-
speciﬁc antisera.
Here, we report the use of these VLPs as a vaccine against RVF. The
safety and immunogenicity were evaluated in mice and the results
indicate that immunization with VLPs confers protection against
challenge with lethal doses of RVFV. These VLPs offer a promising
alternative to attenuated virusmutants as an efﬁcient and safe vaccine
against RVF.
Results
The RVF VLPs are immunogenic and induce virus-neutralizing antibodies
Thirty mice were immunized three times with two weeks
intermission with either 1×105 VLPs/dose, 1×106 VLPs/dose, sterile
PBS or supernatant of cells transfected with all VLP constructs except
the glycoprotein plasmid (Habjan et al., 2009). The two latter groupsconstituted the negative controls. No clinical manifestations derived
from the vaccine were observed in any of these mice. After three
immunizations, the sera were analyzed for the presence of anti-RVFV
speciﬁc antibodies. Immunoﬂuorescense analysis (IFA) performed on
virus-infected mammalian cells showed that all VLP-vaccinated mice
sero-converted and antibodies were detectable at serum dilutions of
up to 1:2700 (Fig. 1A). To analyze the antibody response in more
detail, IFA was performed on mammalian cells transfected with
either cDNA encoding the N protein or the GN/GC proteins (data not
shown). VLP-vaccination induced antibodies towards the GN/GC
protein among all mice, with titers ranging from 300 up to 900.
On the other hand, no detectable N protein speciﬁc antibodies (total
Ig) were observed by IFA after three subsequent VLP-vaccinations
(data not shown).
The virus neutralizing antibody titers were determined by a plaque
reduction neutralization test (PRNT) (Fig. 1B). In the group of mice
administered with 1×105 VLPs/dose, three animals (3/6) showed low
titers, equal to or below 50, the remaining three animals were found to
have neutralizing titers of 250. When the high-dose group adminis-
tered with 1×106 VLPs/dose were analyzed, high titers of neutralizing
antibodies were found; in this dose group, the titer values ranged from
250 to 1250 (Fig. 1B). However, one animal of this group did not
respond to the vaccination, and the neutralizing titer was below 50.
No sero-conversion was detected among the control mice. No
apparent differences in the immune responses, viral replication,
clinical signs, or survival proportions were observed between mice
from the two control groups having received either sterile PBS or a cell
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were consolidated and represent the control.
Vaccination with RVF VLPs protects mice in challenge
The mice were challenged two weeks after the third and ﬁnal
vaccination with a lethal dose (2.4×104 PFU) of RVFV. During the
entire challenge experiment, the mice were monitored twice a day for
signs of infection. The survival proportions among each vaccination
group are shown in Fig. 2. Three out of six mice survived challenge in
the low-dose group, immunized with 1×105 VLPs/dose. Mild clinical
signs were observed among two of the three surviving animals around
day 7 p.i., followed by complete recovery one to two days thereafter.
Eleven out of twelve mice vaccinated with 1×106 VLPs/dose survived
and no clinical manifestations were observed among the surviving
animals during the experimental period. Interestingly, three mice
vaccinated with the lower dose of VLP and onemouse of the high dose
group showing the lowest titers of neutralizing antibodies, as shown
in Fig. 1B, had to be sacriﬁced at days 9 and 10 due to severe clinical
signs. One animal of twelve in the control group survived challenge
without displaying any clinical manifestations. The remaining mice in
the control group displayed severe clinical signs, in some cases as early
as 4 to 5 days p.i., and two control animals developed clinical signs as
late as 12 days p.i. Survival proportionwas signiﬁcantly higher in mice
vaccinated with 1×106 VLPs/dose than in the control group (Chi-
square test, p=0.00004). However, the survival proportion was not
signiﬁcant for the mice in the low-dose group (Fisher exact test,
p=0.0833).
VLP vaccination suppresses sero-conversion against the N protein after
RVFV challenge
Since vaccinationwith the RVF VLPs used in these experiments did
not induce antibodies directed towards the N protein (pre-challenge
sera obtained day 0 p.i., Fig. 3B, C), any detection of anti-N speciﬁc
antibodies after challenge is an indication of viral replication in the
animal hosts. When analyzing sera from the control animals after
challenge (Fig. 3A), anti-N antibodies were clearly observed by ELISA
from days 4 and 5 p.i., followed by increasing and highly individual
titers. However, the VLP-vaccinated mice displayed no or a moderate
rise in the antibody levels (Figs. 3B, C), and the curves are clearly
separated from those of the control animals. The animals in the low-
dose group with slightly elevated titer levels around day 5 p.i. and the
high-dose animals with constantly low antibody titers indicateFig. 2. Percent survival of VLP immunized mice after RVFV challenge. The mice were
vaccinated with either 1×105 or 1×106 VLPs/dose then challenged with 2.4×104 PFU of
RVFV strain ZH548. Mice immunized with a cell suspension or PBS constitute the
control group (Ctrl).
Fig. 3. Antibody response towards the N protein in vaccinated and control animals after
challengewith RVFV. Serum sampleswere collected at different days after challenge and
analysed by ELISA for the presence of speciﬁc antibodies directed against the N protein.
The graphs represent antibody titers in serum samples of panel A control animals,
panel B mice vaccinated with 1×105 VLPs/dose and panel C mice vaccinated with 1×106
VLPs/dose. The curves show the mean value from two separate measurements and the
error bars represent the standard deviation. Incomplete curves correspond to samples
taken from mice that were euthanized early due to a moribund condition.negligible virus replication in the vaccinated animals after challenge.
Only small variations in antibody levels were detected after day 12 p.i.
(data not shown).
VLP immunization inhibits RVFV replication in mice
To further verify if vaccination with VLPs suppresses replication of
the wild-type RVFV after challenge, viral RNA copy numbers in blood
were quantiﬁed using a SYBR-green based qRT-PCR assay (Fig. 4).
When analyzing serum samples of the control and the low-dose mice
(Figs. 4A, B), a great divergence in the detected levels of RNA was
observed between individual mice. A large proportion of the control
Fig. 4. Quantiﬁcation of RVFV RNA in blood samples of VLP-vaccinated and control
animals after challenge. Blood samples were collected before infection (day 0) and on
days three, ﬁve, seven, ten, and twelve after infection and analyzed for the presence of
viral RNA by qRT-PCR. The graphs represent panel A control animals, panel B mice
vaccinated with 1×105 VLPs/dose, and panel C mice vaccinated with 1×106 VLPs/dose.
The curves illustrate RNA copies/ml blood and represent the mean value of two
replicates. The error bars show the standard deviation between measurements.
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of the low-dose group reached their maximum viral load 2 days later
(Fig. 4B). Animals of the high-dose group also displayed a delayed
onset of viral replication (Fig. 4C) and only low viral RNA levels, in
comparison to the other groups, were found (Fig. 4). In conclusion, the
RVF VLPs were found to be safe and highly immunogenic in vivo and
protected mice from lethal challenge by RVFV.
Discussion
RVF is an emerging infectious disease characterized by high
mortality rates among foetuses, neonates, and juvenile livestock and
causes a severe febrile illness also in man. To prevent RVF epidemics
and the concomitant serious socio-economic consequences, new and
improved vaccine strategies are of utmost importance.Recently, VLPs based on the RVFV envelope proteins have been
developed (Habjan et al., 2009), and herein we present the use of
these RVF VLPs as a vaccine in a mouse model. These VLPs, when
analyzed by electron microscopy, have a similar morphology as the
authentic RVFV particles. Moreover, these VLPs display correctly
processed viral glycoproteins in their envelope, proteins that are
recognized by neutralizing antisera and contain transcriptionally
active minigenome-nucleocapsids, but are unable to replicate and
produce progeny (Habjan et al., 2009). In general, VLPs are reported to
have similar properties as the virulent strains of the corresponding
agents since the predominant structural antigens are displayed to the
immune system in a native conformation (Grgacic and Anderson,
2006). The capability of VLPs to confer protective immunity has
previously been demonstrated for a number of viruses. VLPs
assembled from recombinant human papilloma virus capsid proteins
are used as a vaccine against cervical cancer (Harper et al., 2006;
Kirnbauer et al., 1992; Mao et al., 2006; Villa et al., 2005; Zhou et al.,
1991) and VLPs of the small surface antigen of hepatitis B virus (André
and Safary, 1987; McAleer et al., 1984) are also successfully used. In
addition, several preclinical studies have been performed targeting,
e.g., inﬂuenza (Latham and Galarza, 2001; Pushko et al., 2005),
Rotavirus (Bertolotti-Ciarlet et al., 2003; Crawford et al., 1994; Vieira et
al., 2005), and ﬁlovirus infections (Swenson et al., 2005; Warﬁeld et
al., 2004).
Antibody-mediated virus neutralization constitutes an essential
part in the control of infectious agents (Reading and Dimmock, 2007).
In the present study, virus neutralization titers of 250 or more were
found to be protective and associated with survival after challenge. All
mice but one obtained serum neutralizing titers of 250, or more, after
vaccination with the high VLP dose. Similar titers were only found for
half of the animals vaccinated with the lower dose of VLPs. An
unexpected low neutralization titer was found in one animal of the
high-dose group and was probably the cause for the serious clinical
signs that later lead to euthanization of this animal after challenge.
Surprisingly, two of the surviving animals from the low-dose group
displayed mild clinical signs despite the fact that they acquired
neutralizing titers of 250. Three mice of the low-dose group and one
animal of the high dose-group with the lowest neutralizing titers
(equal to or below 50) had to be sacriﬁced at days 9 and 10 due to
severe clinical manifestations. In the control group, themajority of the
animals developed severe clinical signs and high viremia early after
challenge and a large proportion (92%) of the animals succumbed to
infection. One control animal did not display any clinical signs of
infection, although high viral load and anti-N antibodies indicated
extensive RVFV replication. There was a strong association between
the administered VLP dose, neutralizing antibody titers and the
survival rate. Importantly, a signiﬁcant protection (92%) was observed
among the animals administered the high VLP dose in contrast to the
animals in the low-dose group where only 50% survived infection. The
surviving high-dose animals were also clearly distinguished from both
the control and the low-dose animals in the context of viral RNA levels
and anti-N antibody titers detected after infection.
Interestingly, no mouse displayed detectable levels of anti-N
speciﬁc antibodies after VLP vaccination. RVF VLPs do not replicate
and the N proteins present in the interior of the VLP were apparently
not enough to elicit an immune response against the N protein.
However, all mice in this study sero-converted towards the glycopro-
teins after vaccination with the RVF VLPs. The N protein of RVFV is a
major antigen in the early serological response to infection and is
particularly useful during clinical diagnostics and surveillance. Due to
the zoonotic nature of RVF, surveillance is of major importance in the
international trade of animals and animal-related products. Marker
vaccines make it possible to differentiate infected from vaccinated
individuals with speciﬁc diagnostic tests, valuable tools in the
framework of control programs (van Oirschot, 1999). To use the
beneﬁts of marker vaccines fully, it is essential to use easy and
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infected or transfected cells, recombinant N protein based ELISA and
neutralization tests are techniques widely used in laboratories that
specialize in RVFV (Bird et al., 2008; Jansen van Vuren et al., 2007;
Näslund et al., 2008; Zaki et al., 2006). Since VLP vaccination did not
induce an anti-N speciﬁc antibody response, these already established
techniques make it easy to monitor and evaluate future VLP
vaccination programs.
Currently, available RVF vaccines are based on attenuated or
inactivated virus preparations. Because several disadvantages have
been reported when using these vaccines (Lubroth et al., 2007),
attempts to develop new vaccines is a priority. At the moment,
the most advanced and promising live RVFV vaccine candidate is
the recently produced rZH501-ΔNSs:GFP-ΔNSm, which lacks two
RVFV virulence factors, NSs and NSm (Bird et al., 2008). Because
there is a complete deletion of these genes involved in virulence,
it is highly unlikely that the virus can revert to full virulence.
However, other inherent drawbacks of live attenuated vaccines
are -the need for an elevated biosafety level facility for
production and the risk of using attenuated viruses in immuno-
compromised individuals - still remain. When vaccines based on
the VLP strategy are used, the safety concerns and the logistical
disadvantages are circumvented.
Because available RVFV vaccines are associated with deleterious
effects or low immunogenicity, there is an imperative need for the
development of alternative RVF vaccine strategies. We demonstrate
that RVF VLPs are safe and confer protective immunity in mice with
respect to a lethal dose of RVFV. Furthermore, vaccinated individuals
could readily be distinguished from infected with N-speciﬁc diag-
nostic tests. These results clearly show the potential of using VLPs as a
future vaccine candidate against RVF.
Materials and methods
Cells and virus strain
The RVFV strain ZH548 was originally isolated from an
uncomplicated human case that occurred during the Egyptian
outbreak in 1977 (Meegan, 1979; Sall et al., 1999). Low passage
ZH548 stocks were propagated and titrated in conﬂuent monolayers
of Vero E6 cells (ATCC® Number CRL-1586) before used for
challenge. Vero E6 cells were cultivated in Dulbecco's modiﬁed
Eagle's medium (DMEM) (GIBCO, Invitrogen, Carlsbad, CA) supple-
mented with 10% FCS, 10 mM HEPES, and 1 mM sodium pyruvate
and antibiotics (100 U penicillin/ml, 100 μg/ml streptomycin). For
immunological methods, BHK-21 cells (ATCC® Number, CCL-10)
were maintained in Glasgow MEM (GIBCO, Invitrogen) and supple-
mented with 5% FCS, 1.3 g/l Tryptose (Difco™, Becton, Dickinson and
Company, Sparks, MD), 10 mM HEPES, and 1 mM sodium pyruvate
and antibiotics (100 U penicillin/ml, 100 μg/ml streptomycin).
Human 293T (ATCC® Number CRL-11268) cells were cultivated in
DMEM and supplemented with 10% FCS, 0.4% sodium hydrogen
carbonate, 1 mM sodium pyruvate, 0.53 mg/ml glutamine, and
antibiotics (100 U penicillin/ml, 100 μg/ml streptomycin). All cells
were cultivated at 5% CO2 at 37 °C.
VLP production and puriﬁcation
Subconﬂuent monolayers of 293T cells in 90 mm dishes were
transfected with 3 μg of plasmids pI.18_RVFV_N, pI.18_RVFV_L,
pI.18_RVFV_M, and pHH21_RVFV_vMRen (Habjan et al., 2009)
using Nanofectin (PAA Laboratories, Linz, Austria) transfection
reagent. Two days post transfection, supernatants were collected
and clariﬁed from cell debris by centrifugation (6000 ×g, 10 min at
4 °C). The particles were then concentrated by ultracentrifugation at
24,000 rpm at 4 °C for 2 h in a Beckman SW41Ti rotor. The pelletwas dried for 5 min before being re-suspended in phosphate-
buffered saline (PBS). To deﬁne the titer, VLPs expressing GFP were
generated and concentrated in parallel to the Ren-VLPs which were
used for the vaccinations. BSR-T7/5 cells expressing RVFV L and N
(Habjan et al., 2009) were incubated for 1 h with ten-fold serial
dilutions of supernatants containing GFP-VLPs. Twenty-four hours
later the number of GFP-positive (i.e. VLP-infected) cells was
determined by ﬂuorescence microscopy and the titer of the GFP-
VLP preparation was calculated accordingly. The titer of the Ren-
VLPs was estimated to be in the same range. Western blot analysis
conﬁrmed that the amounts of GFP-VLPs and Ren-VLPs were
comparable.
VLP immunization
This study used 33 female C57BL/6 mice (Scanbur BK) 6–
7 weeks old. The mice were kept in cages under BSL-2 conditions
during the whole vaccination routine with free access to food and
water. Two VLP doses were administered, 1×105 VLPs/dose (n=6)
and 1×106 VLPs/dose (n=12). To serve as negative controls, 12
mice were inoculated with either sterile PBS (n=5) or with a cell
supernatant (n=7), similar to what was used in the production of
the RVF VLPs. Two independent vaccinations were performed with
comparable immunization schedules and different batches of VLPs,
although the second round did not include the lower dose group.
All animals were vaccinated intraperitoneally (i.p.) three times
(two weeks intermission) with the VLPs diluted in sterile PBS to a
ﬁnal volume of 200 μl.
RVFV challenge
Two weeks after the third vaccination, a challenge dose
containing 2.4×104 PFU of RVFV strain ZH548 were administered i.
p. During these procedures, the mice were kept individually in
micro-isolator pans within an animal isolator (Bell Isolation Systems
Ltd, Scotland, UK). All manipulations with infected mice and/or
samples involving RVFV were performed strictly under BSL-3
conditions. The animals were examined twice daily for visual signs
of illness until the experiments were ended, 12–14 days post
infection (p.i.). Clinical signs observed among mice after infection
ranged from distress, rufﬂed fur, and weight loss to fatigue,
neurological manifestations, and a “hunchback-like” posture. Mice
found in a moribund condition were instantly euthanized. Blood
samples were collected before each immunization and every second
or third day p.i. To ensure a sterile milieu, non-infected mice (n=3)
were kept under the same conditions during the entire experiment.
This project was approved by The Animal Research Ethics Commit-
tee of Umeå University, Sweden.
Plaque reduction neutralization test (PRNT)
Heat inactivated sera, collected two weeks after the third
immunization, were ﬁve-fold serially diluted in sterile PBS and
incubated with a virus suspension containing 30 PFU of ZH548 before
adsorption to a conﬂuent monolayer of BHK-21 cells. After a 90 min
incubation period and subsequent washing, the cells were covered
with an overlay containing 1% CMC (Carboxy-Methyl Cellulose,
Aquacide II, Calbiochem®, California, USA) prepared in maintenance
DMEM and incubated for six days at 37 °C/5% CO2. After ﬁxation with
10% formaldehyde, the plaques were visualized by counterstaining
with 1% crystal violet in water containing 20% ethanol and 0.7% NaCl
and counted after destaining with tap water. Sera of non-infected or
infected mice constituted the negative and positive controls, respec-
tively. The neutralizing antibody titers were determined as the
reciprocal of the highest serum dilution that reduced the number of
plaques by 80%.
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assay (ELISA)
For IFA, BHK-21 cells were infected with RVFV (strain ZH548) at a
multiplicity of infection (MOI) of 1 or transfected and grown on cover
slips. Transfectionwasperformed using the eukaryotic expression vector
(pcDNA3.1, Invitrogen) containing cDNA encoding the N protein or the
open reading frame of the GN/GC proteins and FuGene 6 transfection
reagent (Roche Inc.) according to the manufacturer's instructions. The
cells were ﬁxed in 4% paraformaldehyde and permeabilized with 0.2%
Saponin in PBS 36 h p.i. or 48 h post transfection. After incubation with
three-fold serial dilutions of the serum samples, collected two weeks
after the third vaccination, infected or transfected cells were labelled
using a goat anti-mouse Alexa Fluor™ 488 conjugate total Ig or a FITC
conjugated rabbit anti-mouse total Ig, respectively, according to the
instructions of the manufacturers (Molecular Probes, Invitrogen).
ELISA was performed as described earlier (Näslund et al., 2008)
using recombinant N-protein (GenBank accession no. AF134534) (Sall
et al., 1999) of RVFV and constructed and puriﬁed as previously
described (Le May et al., 2005; Lindkvist et al., 2007). The sera used
were collected at the day of infection (day 0) then three, ﬁve, seven,
ten and twelve days p.i. The serum samples were prepared as four-fold
serial dilutions, and the antibody titers were calculated as the inverse
dilution at the intersection of the straight line and the x-axis. Serum
samples from pre-bleedings and non-infected mice were present on
each plate to determine unspeciﬁc reactivity.
Quantitative real time reverse transcriptase PCR (qRT-PCR)
The viral load was measured in blood, collected at the day of
infection (day 0) and day three, ﬁve, seven, ten, and twelve p.i, using a
qRT-PCR as previously described (Näslund et al., 2008). Brieﬂy, RNA
was extracted and puriﬁed using Trizol LS (Invitrogen) and RNeasy
Mini Kit (Qiagen Inc.) in accordance to the manufacturer's instruc-
tions. cDNA were synthesized using SuperScript™ III RT according to
manufacturer's instructions (Invitrogen). qRT-PCR was performed in
24 μl reactions using SYBR-green (Biotools, B&M Labs, Madrid, Spain)
with primers targeting the S-segment of RVFV (available from the
authors upon request).
Statistical methods
Survival proportions were compared using Chi-square test and
Fischer exact test for values under ﬁve (Epi Info™, Version 3.5).
Quantitative variables were based on measurements of a minimum of
two independent experiments containing duplicate samples. Vari-
ables are expressed as means, and the error bars correspond to the
standard deviation between the replicates.
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